What indicators would you like to setup a trade for?

Candlestick Daily volume index Bar reversal Edit

Trade setup

Position Order Entry Exit Stop Loss Risk Return Expectancy
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?

Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%



Code Company Date Close Change Indicator Value Signal

Trading Performance




Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 21 17.9 0.38% 0.62% 16.3% -5.8% 54.7%
SHORT 20 17.9 0.25% 0.31% 7.8% -8.5% -97.8%


Technical Analysis

Opthea (OPT.AX)



Last Signal:


Trading: HOLD @ $3.61
Signal Strength: STRONG

Opthea (ASX:OPT) currently has positive MACD of 0.0412. Currently the signal line is greater than the MACD line signalling a bullish movement.

Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. This indicator has the ability to detect the speed of movement & give an early signal for a potential movement. By understanding the rate at which the price is moving in respect to the stocks historical trades, enables positions to be set in place based on changes in the speed of movement

Moving Average Convergence/Divergence (MACD) is an indicator that shows the relationship between two moving averages. It is calculated as a difference between the fast and slow moving averages. The historically popular is the difference between a securities 26-day and 12-day Exponential Moving Averages (EMA).

Calculation:: Moving Average Convergence Divergence (MACD);
1) MACD Line: (12-day EMA - 26-day EMA);
2) Signal Line: 9-day EMA of MACD Line;
3) MACD Histogram: MACD Line - Signal Line;


Stock Exchange: ASX
Company: Opthea
Ticker Codes: | OPT.AX | ASX:OPT |

About Opthea (ASX:OPT):

Opthea Limited develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) C and D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3, which is in Phase 1/2A clinical trial for the treatment of back of the eye diseases, such as wet age-related macular degeneration that is the cause of blindness in elderly and diabetic populations. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited is based in South Yarra, Australia.

Top 10:


Company Close Change(%) Volume Value Signal
MVP Medical Developments 10.28 8.8 674,204 0 BEARISH CROSSOVER
CAT Catuity 2.17 3.8 509,665 -0.01 BEARISH CROSSOVER
CGC Consolidated Gaming Corporation 2.75 3.4 1,912,548 -0.01 BEARISH CROSSOVER
CIM Cimic 28.88 3 1,361,103 -0.04 BEARISH CROSSOVER
PPH Pan Pharmaceuticals 4.4 2.6 25,572 0 BEARISH CROSSOVER
OGC Oceanagold Corporation 2.69 1.1 439,658 -0.01 BEARISH CROSSOVER
FBU Fletcher Building 5.45 0.9 472,833 0 BEARISH CROSSOVER
TWE Treasury Wine Estates 17.7 0.2 1,906,546 -0.02 BEARISH CROSSOVER
IRE Iress Market Technology 13.43 0.1 212,504 0 BEARISH CROSSOVER
GGG Greenland Minerals 0.12 0 918,457 0 BEARISH CROSSOVER